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Iron overload coupled with low hepcidin levels are characteristics of hereditary haemochromatosis. To understand the role of transferrin receptor (TFR) and intracellular iron in hepcidin secretion Chinese hamster ovary transferrin receptor variant (CHO TRVb-1) cells were used that express iron-response-element-depleted human TFRC mRNA (TFRC∆IRE). Results showed that CHO TRVb-1 cells expressed higher basal levels of cell-surface TFR1 than HepG2 cells (2.2-fold; p<0.01) and following 5 g/L holotransferrin treatment maintained constitutive over-expression at 24 h and 48 h, contrasting the HepG2 cells where the receptor levels significantly declined. Despite this, the intracellular iron content was neither higher than HepG2 cells nor increased over time under basal or holotransferrin-treated conditions. Interestingly, hepcidin secretion in CHO TRVb-1 cells exceeded basal levels at all time-points (p<0.02) and matched levels in HepG2 cells following treatment. While TFRC mRNA expression showed expected elevation (2 h, p<0.03; 4 h; p<0.05), slc40a1 mRNA expression was also elevated (2 h, p<0.05; 4 h, p<0.03), unlike the HepG2 cells. In conclusion, the CHO TRVb-1 cells prevented cellular iron-overload by elevating slc40a1 expression, thereby highlighting its significance in the absence of iron-regulated TFRC mRNA. Furthermore, hepcidin response to holotransferrin treatment was similar to HepG2 cells and resembled the human response.











Hepcidin is a liver-secreted, 25-mer peptide hormone responsible for maintaining iron homeostasis in the body [1]. Systemic iron elevation leads to increased levels of hepcidin that binds to ferroportin, the cellular iron-exporter, and induces internalisation and degradation of both hepcidin and ferroportin [2]. Thereby, it prevents cellular iron-efflux and regulates systemic iron levels. However, the iron-sensing mechanisms that lead to hepcidin secretion are unclear. A putative role of transferrin receptor (TFR)1 in modulating hepcidin expression was suggested [3] but its significance in transferrin-sensing and hepcidin induction has not been sufficiently emphasised. Likewise, even though an involvement of intracellular iron in the maturation of prohepcidin into bioactive hepcidin was postulated [4], its function in hepcidin peptide secretion has not been sufficiently examined. This is partly because of lack of suitable cell lines that could consistently mimic the human hepcidin response to iron treatments. Also, majority of previous ex vivo iron supplementation studies and even some current investigations focussed on transcriptional regulation of hepcidin [5] and not on bioactive hepcidin peptide. 






Materials and Methods 
Cell culture 
Wild type (Wt) CHO and CHO TRVb-1 clone B6, donated by Professor Keith Caldecott (University of Sussex, UK) and Dr. Heinz Zoller (University of Innsbruck, Austria), respectively, were maintained in Ham’s F12 nutrient mixture (1X) (Invitrogen, UK) with 2 mM glutamax (Fisher Scientific,UK), 10 % foetal calf serum (FCS) (Biosera, UK) and 1 % antibiotic/antimycotic solution (100X) (Fisher Scientific, UK). HepG2 cells (Health Protection Agency, UK) were maintained in Eagle’s Minimum Essential Medium (EMEM) (Sigma-Aldrich, UK).

Iron treatment studies
Apo-Tf was iron-loaded using 0.1 M ferric citrate and iron saturation of 5 g/L holo-Tf was confirmed by polyacrylamide gel electrophoresis using a 6 M urea gel [8]. Iron concentration in holo-Tf treatment medium was determined by ferrozine assay [9]. Cells were seeded at a density of 5 X 105 cells in a 6-well plate and maintained until 60 % - 70 % confluent. After washing with phosphate buffered saline (PBS) (Invitrogen, UK), cells were treated with serum-free EMEM (0 g/L) or 5 g/L holo-Tf from 30 minutes (min) to 24 h and various parameters were assessed, as described below. 

Detection of human transferrin receptor at mRNA and protein levels in CHO TRVb-1 cells 
To detect TFRC transcripts in CHO cells, PCRs were conducted with cDNA as template and primers listed in the succeeding section. Human TFR1 protein in the CHO TRVb-1 cells was confirmed by immunoblotting. Cell pellet was mixed with 2X Laemmli buffer and loaded on 10 % SDS gels (BIO-RAD, UK.) After electrophoresis, proteins were transferred to a PVDF membrane and blocked with 10 % fat-free milk in PBS for 1 h at room temperature (RT). Membranes were probed with primary human TFR1 antibody 3B82A1 (Thermo scientific, UK) [1:2000] for 1 h at RT and then incubated with a rabbit anti-mouse HRP-conjugated secondary antibody (Dako Ltd, UK) [1:1000] for 1 h at RT. Bands were visualised using ECL™ Western Blotting Detection Reagents (GE healthcare, UK) on X-ray film.

For analysis of cell-surface TFR1 expression, cells were harvested using TrypLE Express (ThermoFisher Scientific, UK), followed by centrifugation for 4 min at 89 x g. Cells were suspended in PBC (PBS containing 0.15 % BSA and 1 mM calcium chloride) and transferred to a 96-well plate (2 X 105 cells per well) and centrifuged at 1,260 x g for 30 sec. To each well, 20 µL of 16 mg/mL blocking IgG was added. Human transferrin receptor antibody (Abcam, UK) [5 µg/mL in PBC)] was added to each test well and PBC was added to the control wells. Cells were incubated for 45 min on ice. Following washing, the cells were incubated with 10 µg/mL of FITC-labelled secondary antibody STAR9B  rabbit F (ab')2 anti-mouse IgG (ABD Serotec, UK). After incubation for 30 min on ice, cells were washed with PBC again. Cell layer at the bottom of each well was resuspended in 400 µL of PBS and TFR1 expression was analysed by  flow cytometry [10]. 

Determination of intracellular iron content and hepcidin peptide levels and mitochondrial activity
Cellular iron content, as determined by the ferrozine assay [9], was expressed as nmoles of iron per mg of protein, as quantified by the Bradford method. The ferrozine assay can detect levels from 2 to 300 µM and compares favourably to atomic absorption spectroscopy [9] and and ICP-MS [11]. The concentration of hepcidin peptide secreted in the cell media was measured as described by Busbridge et.al [12]. Here, using a rabbit anti-human hepcidin antibody, plasma hepcidin ranges from 1.1–55 ng/mL, with a median of 10.8 ng/mL in healthy controls, while the limit of detection is 0.6 ng/mL and linearity is up to 200 ng/mL [12]. The mitochondrial activity was assessed using the MTT assay [13]. 

Primer design, cDNA synthesis, sequencing and gene expression analyses 
Primers were designed through software Primer 3 (http://frodo.wi.mit.edu/ (​http:​/​​/​frodo.wi.mit.edu​/​" \t "pmc_ext​)). Primers CCCAGCAGAAGCATTATCTTT (F) and TTCCCATCAATTGGATGTCTT (R) for CHO-endogenous TfRC and AAAATCCGGTGTAGGCACAG (F) and TTAAATGCAGGGACGAAAGG (R) for human TFRC were used to detect TFRC transcripts in CHO cells. For gene expression analyses, the primers AAAATCCGGTGTAGGCACAG (F) and TTAAATGCAGGGACGAAAGG (R) for human TFRC, ATGGGTGCTCACTGTCTGCTA (F) and  GCATTCATATCTGCTAATCTGCTTC (R) for CHO-slc40a1, GCTCTTTTCCAGCCTTCCTT (F) and GAGCCAGAGCAGTGATCTCC (R) for CHO- beta-actin [14], TGTTTCTGGTAGAGCTCTAT (F) and GATATAGCAGGAAGTGAGAA (R)  for human SLC40A1 and GCCAAAAGGGTCATCATCTC (F)  and GGTGCTAAGCAGTTGGTGGT (R)  for GAPDH [15] were used. RNA was extracted using the TRI reagent (Sigma-Aldrich, UK), reverse transcription and cDNA synthesis was performed using QuantiTect reverse transcription kit (Qiagen, UK) and PCRs were performed using Taq PCR master mix (Qiagen, UK). All PCR products were sequenced to confirm product identity. Prior to sequencing, amplicons were electrophoresed on 1 % agarose gel (Web Scientific, UK) to confirm product size and purified using PCR product purification kit (Qiagen, UK). Sequencing was conducted at the Wolfson Institute for Biomedical Research (University College London, UK). Gene expression was analysed through real-time PCR using Qiagen’s Quantifast SYBR green kit in Rotor-gene Q machine (Qiagen, UK) and results were analysed using Rotor-gene software series 1.7. Data was expressed as 2-∆∆Ct [16]. 

Characterisation of slc40a1 sequence in CHO TRVb-1 cells 
DNA was extracted using the isopropanol-ethanol precipitation method [17]. To characterise the previously unknown slc40a1 sequence in CHO TRVb-1 cells, genomic similarities between related species were assessed (supplementary Table 1) and “PCR walking” was used (supplementary information). Characterised CHO-slc40a1 gene sequence was translated to its protein sequence (referred as CHO-ferroportin) by using the TRANSLATE tool (http://web.expasy.org/translate (​http:​/​​/​web.expasy.org​/​translate​/​​)) and compared with ferroportin sequences of human, mouse and rat (supplementary Table 2) by using ClustalW2 (www.ebi.ac.uk (​http:​/​​/​www.ebi.ac.uk​)).

Bioinformatics analysis of hepcidin peptide sequences
To assess peptide sequence similarities between human and Chinese hamster, multiple sequence alignments were created via CLUSTAL O (1.2.1) available via UniProtKB (supplementary Table 2). 

Statistical analysis
Data was analysed by using one-way or two-way ANOVA, accompanied by post-hoc analysis by Tukey’s test using the software SPSS, version 19. The level of significance was set at p<0.05.

Results
Characterisation of CHO TRVb1-cells in basal conditions
TFR1 expression: Presence of human TFRC mRNA and absence of CHO-endogenous Tfrc mRNA in CHO TRVb-1 cells was confirmed (Fig.1a). Here, only wt CHO cDNA formed product with primers for CHO-endogenous Tfrc (lane 1). As expected, CHO TRVb-1 cDNA did not form product with primers for CHO-endogenous Tfrc but formed product with primers for human TFRC (lanes 3 and 4, respectively). Human TFR1 protein in the CHO TRVb-1 cells showed expected bands of approximately 180 kDa (lane 1) and 85-90 kDa (lane 2) under non-reducing and reducing conditions, respectively (Fig.1b), as previously observed [18]. Also, the CHO-TRVb1 cells showed significantly higher levels of cell-surface TFR1 than HepG2 cells (2.2-fold; p<0.01) (Fig.1c).
Intracellular iron content and hepcidin secretion: Under basal conditions, CHO TRVb-1 cells maintained intracellular iron content over time and did not differ significantly from HepG2 cells (Fig.2a). Hepcidin secretion in CHO TRVb-1 cells declined over time from 30 min to 2 h (p<0.05), followed by substantial reduction at 24 h (3.6-fold; p<0.01), while the HepG2 cells showed constant hepcidin levels (Fig.2b). The CHO TRVb-1 cells secreted significantly lower levels of hepcidin than HepG2 cells at 2 h (p<0.04) and 24 h (p<0.02).

Iron supplementation studies in CHO TRVb-1 cells 
Analysis of iron saturation of holo-Tf indicated that 90 % of the protein was diferric, with a minor proportion of monoferric transferrins (supplementary Fig.2a). Also, iron content in 5 g/L holo-Tf treatment medium was determined as 105 µM, which was 84 % of the expected iron molarity of 125 µM in a 5 g/L holo-Tf preparation (supplementary Fig.2b). 
Cell-surface TFR1 expression: Upon 5 g/L holo-Tf treatment, the CHO TRVb-1 cells maintained elevated TFR1 expression at 48 h, contrasting the HepG2 cells where TFR1 levels significantly declined from 24 h to 48 h (p<0.01) (Fig.3). 
Intracellular iron content: Following holo-Tf deprivation (0 g/L), the CHO TRVb-1 cells neither showed significant variation in intracellular iron content over time nor differed in iron content from the HepG2 cells (Fig.4a). Upon holo-Tf treatment (5 g/L), the CHO TRVb-1 cells showed significantly reduced intracellular iron content from 30 min to 4 h (2.2-fold; p<0.01) (Fig.4b). However, the levels significantly increased from 4 h to 24 h (p<0.05) and restored iron levels to that observed at earlier time points. Iron levels did not majorly differ from the HepG2 cells, except at 4 h (p<0.02) (Fig.4b).
Hepcidin levels: Holo-Tf deprivation in CHO TRVb-1 cells (Fig.4c) caused a significant decline in hepcidin secretion over time from 30 min to 24 h (2.8-fold; p<0.01). The levels were similar to HepG2 cells, except at 4 h where the levels in CHO TRVb-1 cells were higher than levels in HepG2 cells (1.9-fold; p<0.02). Upon holo-Tf treatment, the CHO-TRVb-1 cells exceeded basal hepcidin secretion levels at all time-points (p<0.02), but it decreased from 30 min to 24 h (1.8-fold; p<0.01), unlike the HepG2 cells that maintained constant levels (Fig.4d). Hepcidin levels in CHO TRVb-1 cells were similar to HepG2 cells, except at 24 h where the CHO TRVb1 cells secreted significantly lower levels than HepG2 cells (1.7-fold; p<0.02).
 Gene expression analysis: Holo-Tf deprivation in CHO-TRVb1 cells significantly increased TFRC expression at 4 h (3.3-fold; p<0.05) and significantly reduced slc40a1 expression at 2 h (p<0.03) and 24 h (p<0.05) (Fig.5a). Holo-Tf treatment to CHO TRVb1 cells significantly increased TFRC expression at 2 h (3.2-fold; p<0.03) and 4 h (5.9-fold; p<0.05) (Fig.5b) slc40a1 expression was significantly elevated at 2 h (2.2-fold; p<0.05) and 4 h (3.4-fold; p<0.03), which followed a substantial decrease at 24 h (p<0.01). In the HepG2 cells, holo-Tf deprivation caused an insignificant increase in TFRC expression (3.6-fold; p=0.09) and a significant decrease in SLC40A1 expression at 24 h (p<0.03) (Fig.5c). Following holo-Tf treatment, TFRC expression significantly increased at 2 h (3-fold; p<0.01) whereas SLC40A1 expression significantly decreased at 4 h (p<0.05) (Fig.5d). 
Mitochondrial activity: The CHO TRVb1 and HepG2 cells did not show any major change in mitochondrial activity under holo-Tf deprived and supplemented conditions (Fig.6).

Characterisation of slc40a1 in CHO TRVb1-cells 
To enable gene expression analyses, the previously unknown sequence of CHO-endogenous slc40a1 was partially characterised (Fig.7). These characterised sequences displayed very high percentage similarities with corresponding slc40a1 sequences in human (>88%), mouse (>90%) and rat (>90%) (Fig.7b). Partial alignment of the sequence is shown in supplementary Fig.1. The characterised CHO-slc40a1 sequence was translated into a protein sequence and compared with ferroportin sequences in other species. Data showed conservation of many functionally significant domains in the proposed transmembrane region and the hepcidin binding region in ferroportin (Fig.7c). Particularly conserved were N144 and V162, which if mutated, exhibit hepcidin insensitivity. The position of C326 in relation to other amino acids is also conserved in the proposed hepcidin binding region, lying outside the transmembrane region and therefore appears to be consistent with its role in binding to hepcidin. K253, Y302 and Y303, which are involved in ferroportin internalisation and degradation upon hepcidin binding are conserved in this characterised CHO-slc40a1 sequence and are located in the same position relative to other amino acids as in human, mouse and rat ferroportin [19]. Also, cysteines which form disulphide bonds and usually play a significant role in the folding and stability of proteins [20], are well conserved. 


Bioinformatics analysis of hepcidin 
Peptide sequence similarities between hamster and other species were assessed. The two predicted hepcidin isoforms in Chinese hamster [21] bear 84 % sequence similarity with each other (Fig.8a) and the terminal 25-mer region bears 84 % sequence similarity with human hepcidin-25 (Fig.8b). Specifically, the first eleven amino acids at its N-terminus are identical to corresponding positions in human hepcidin-25, except that threonine at position 2 in human hepcidin-25 is replaced by serine, which has a side chain similar to threonine. Moreover, there is 100 % conservation of the eight functionally and structurally significant cysteines [22] (Fig.8b).

Discussion
Here, the effect of excess holo-Tf on intracellular iron levels and hepcidin secretion was examined in the CHO TRVb-1 cells that possess iron-unregulated TFRC mRNA (TFRC∆IRE) [6] and compared with the HepG2 cells that possess iron-regulated human TFRC mRNA. A high concentration of 5 g/L holo-Tf was chosen to promote intracellular iron overload as previous holo-Tf supplementation studies at 2.5 g/L holo-Tf showed no effect on hepcidin mRNA [23] and 30 µM holo-Tf (1.2 g/L) gave conflicting results with either up regulation [24] or down regulation of hepcidin mRNA [25]. On the other hand, when 100 µM holo-Tf (approximately 4 g/L) was used for treatment, an increase in hepcidin mRNA expression was observed [26].  It is also important to note that non-Tf bound iron (NTBI) may play a role in iron uptake. However, pathways for NTBI uptake are less clearly defined compared to TBI uptake. In addition, several previous studies with NTBI showed no effect [1, 24] or even down regulation [15, 25, 27] of hepcidin mRNA. Moreover, the holo-Tf treatment medium was prepared in serum-free Eagle’s Minimal Essential Medium (EMEM) that is deprived of inorganic iron sources. This was confirmed by the ferrozine assay, which showed no detectable iron levels in this medium, denoted as 0 g/L (supplementary Fig. 2b), while it showed approximately 6 µM in a FCS (10%)-supplemented EMEM. Thus, the current findings are only based on holo-Tf treatment.

Cellular iron regulation and characterisation of hepcidin response 
Human TFRC at mRNA and protein levels were confirmed in CHO TRVb-1 cells (Fig.1a and 1b). The cells expressed 2.2-fold higher basal levels of cell-surface TFR1 than HepG2 cells (Fig.1c). Following 5 g/L holo-Tf treatment, the HepG2 cells significantly decreased cell–surface TFR1 expression over time (Fig.3c) and demonstrated an expected iron-regulated response where TFRC transcripts are sensitive to intracellular iron sufficiency due to the IRE region [7] and subsequently decrease cell-surface TFR1 to avoid further iron-uptake, as confirmed here. Contrastingly, the CHO TRVb-1 cells showed constantly elevated expression despite prolonged extracellular holo-Tf excess; a dysregulated characteristic of cell-surface TFR1 in these cells demonstrated in this study for the first time (Fig.3c). This dysregulation due to TFRC∆IRE was also reflected at mRNA level where despite excess extracellular holo-Tf, TFRC mRNA expression significantly increased at 2 h and 4 h (Fig.5b). 

Although the constitutively high expression of cell-surface TFR1 (Fig.3c) and TFRC∆IRE together indicated a potential for increased iron-uptake, surprisingly, the CHO TRVb-1 cells neither showed higher intracellular iron levels than HepG2 cells under basal conditions (Fig.2a) nor majorly increased iron-uptake upon holo-Tf supplementation (Fig.4b), contrary to the expected. This could be attributed to the elevated slc40a1 expression, as observed at 2 h of holo-Tf treatment to promote cellular iron-efflux [28] and circumvent any potential increase in iron content caused by increased TFRC mRNA expression at the same time (Fig.5b). Accordingly, at 4 h of holo-Tf treatment, a 3.2-fold increase in slc40a1 expression corresponded to a 2.2-fold decrease in intracellular iron content (Fig.5b and Fig.4b). Such elevations in slc40a1 expression are consistent with the iron-sensitive feature of the IRE region on slc40a1 mRNA [29]. This feature prevented cellular iron overload in CHO TRVb-1 cells and did not allow iron levels to exceed beyond that in HepG2 cells, which showed constant levels of SLC40A1 mRNA expression (Fig.5d).
Interestingly, the CHO TRVb-1 cells are similar to cancer cells that also over-express cell-surface TFR1 to acquire iron for cell survival, growth and proliferation [30]. However, while the human breast cancer cells showed reduced ferroportin expression compared to non-malignant cells [31], presumably to retain intracellular iron, the CHO TRVb-1 cells differed and showed elevated slc40a1 expression, aiming for iron-efflux (Fig.5). Thus, unlike cancer cells, the CHO-TRVb1 cells exhibited a fascinating regulatory phenomenon where scl40a1 maintained intracellular iron-homeostasis in presence of excess extracellular holo-Tf and abundant cell-surface TFR1, while TFRC mRNA was incapable of contributing to intracellular iron-sensing due to TFRC∆IRE. The overall aim of protecting the cells from excess-iron-mediated toxicity was achieved, as confirmed through the MTT assay, which showed no signs of cell toxicity (Fig.6). 

Here, we presented novel data where the CHO TRVb-1 cells secreted hepcidin under basal conditions; and following holo-Tf treatment, exceeded basal levels at all time-points (Fig.2b and Fig.4d). This resembled the human response to excess systemic iron levels [1] and suggested that these cells were suitable to study holo-Tf-induced hepcidin responses. The antibody utilised detects the N-terminal 14 amino acid region of human hepcidin-25 [12], (Fig. 8b, amino acids in bold). Here, 12 out of the total 14 amino acids are identical to the corresponding region in hamster hepcidin (Fig. 8b, highlighted grey). Moreover, in position-2 of human hepcidin-25, threonine in human is replaced by a structurally and functionally similar amino acid serine in hamster. This leaves only one dissimilar amino acid at position 12. Such high level of similarity in the antibody binding region of hepcidin-25 fully supports the successful detection of hamster hepcidin by this method. The method used here has also been successfully used to detect hepcidin in rhesus monkeys [32]. 

Under basal conditions, the CHO TRVb-1 cells secreted significantly lower levels of hepcidin than HepG2 cells (Fig.2b). Since HepG2 cells are of hepatic origin whereas CHO TRVb-1 cells are ovary-derived, this data is consistence with the tissue–specific nature of hepcidin, where, in human and animals, hepcidin is predominantly secreted by liver hepatocytes with lower amounts being secreted by other tissues [33], however the peptide expression level has been reported higher in rat kidney than human kidney by immunoblot analysis [34]. Also, overexpressed TFR1 expression on the cell-surface may have disturbed its physiological ratio with HFE and TFR2, the hepcidin inducing proteins [35], thereby causing lower hepcidin secretion under basal conditions. However, upon holo-Tf treatment, hepcidin levels in CHO TRVb-1 cells matched the levels in HepG2 cells, at least up to 4 h (Fig.4d), which indicated that tissue-specificity was overruled and hepcidin response to holo-Tf treatment governed. This may have occurred via two mechanisms; first, upon binding of holo-Tf to TFR1, the TFR1-bound HFE may be displaced and free to bind to TFR2 to induce hepcidin [3] and second, due to the predominance of response–specific factors over tissue-specific factors [36]. Since, the expected intracellular iron overload was not achieved, exactly how and to what extent intracellular iron levels modulate hepcidin secretion remains to be elucidated. 

Characterisation of CHO-slc40a1 and bioinformatics study of hepcidin peptide sequences
In order to study iron-efflux in CHO TRVb-1 cells and cellular iron regulation via real-time PCR, genomic similarities between species were examined (supplementary Table 1) and partial characterisation of the previously unknown slc40a1 sequence in CHO TRVb-1 cells was achieved (Fig.7a and 7b). As expected, the characterised slc40a1 sequences in CHO TRVb-1 cells bore more than 88 % sequence similarities with the corresponding sequences of human, mouse and rat (Table 1) and were subsequently used to design primers for gene expression analysis  (Supplementary Fig.1, Fig.5a and 5b). Comparison of the characterised and then translated CHO-slco40a1 sequence with ferroportin sequences from other species showed an overall 92 % similarity. Several amino acids in the functionally significant domains such as the proposed transmembrane region and hepcidin binding region are conserved, as presented here for the first time (Fig.7c). Overall, the data indicates that the sequence of ferroportin is well conserved amongst species.
	The two hepcidin isoforms of Chinese hamster [21] show high sequence similarity with human hepcidin-25 (Fig.8b). This is particularly in the N-terminal region that is important for its interaction with ferroportin, the furin cleavage site on prohepcidin that releases bioactive hepcidin and the 8 cysteine residues, which are believed to have structural and functional significance [22]. 

Conclusion 
Despite the substantially higher levels of cell-surface TFR1, intracellular iron overload was not achieved in CHO TRVb-1 cells, possibly due to elevated slc40a1 expression. This demonstrated the importance of the iron–efflux protein ferroportin in maintaining intracellular iron homeostasis in the absence of iron-regulated TFRC mRNA. Furthermore, we have demonstrated novel data whereby CHO-endogenous hepcidin secretion occurred under basal conditions and was further stimulated upon 5 g/L holo-Tf stimulus, resembling the human response to iron treatment.
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Abbreviations: 
CHO       Chinese hamster ovary 
EMEM    Eagle’s minimal essential medium
H             Hours
IRE          Iron responsive element
IRP          Iron regulatory protein 
Min         minutes
MTT        3-(4,5-Di (​http:​/​​/​en.wikipedia.org​/​wiki​/​Di-" \o "Di-​)methyl (​http:​/​​/​en.wikipedia.org​/​wiki​/​Methyl" \o "Methyl​)thiazol (​http:​/​​/​en.wikipedia.org​/​wiki​/​Thiazole" \o "Thiazole​)-2-yl)-2,5-diphenyl (​http:​/​​/​en.wikipedia.org​/​wiki​/​Phenyl" \o "Phenyl​)tetrazolium bromide
PCR        Polymerase chain reaction
Sec          Seconds
Slc40a1   Gene encoding the iron-exporter protein ferroportin
Tf            Transferrin
TFR         Transferrin receptor
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Figure captions  
Fig.1 TFRC transcripts and protein in CHO-TRVb-1 cells
Fig.2 Iron and hepcidin levels in CHO TRVb-1 cells under basal conditions 
Fig.3 Cell-surface TFR1 in CHO-TRVb-1 cells following iron treatment 
Fig.4 Iron and hepcidin levels in CHO TRVb-1 cells following iron treatment
Fig.5 mRNA expression of human TFRC and endogenous slc40a1 in CHO TRVb-1 cells
Fig.6 Mitochondrial activity in CHO TRVb-1 cells following iron treatment 
Fig.7 Characterisation of slc40a1 in CHO TRVb-1 cells









Fig.1 TFRC transcripts and TFR1 protein in CHO TRVb-1 cells  
(a): The cDNA from CHO TRVb-1 and Wt CHO cells was amplified and run on 1 % agarose gel. Lane 1= Amplicon of Wt CHO cDNA obtained by using CHO-endogenous TfRC primers; expected product-size is 230 bp; lane 2= PCR of Wt CHO cDNA with human TFRC primers; no product expected; lane 3= PCR of CHO TRVb-1 cDNA with CHO-endogenous TfRC primers; no product expected; lane 4= Amplicon of CHO TRVb-1 cDNA obtained by using human TFRC primers; expected product size is 179 bp.
(b): Cell pellet of CHO TRVb-1 cells was probed with human TFR1 antibody and Western blot detected human TFR1 protein in CHO TRVb-1 cells. Lane 1= CHO TRVb-1 cells in non-reducing conditions; lane 2= CHO TRVb-1 cells in reducing conditions. 
(c): Cell-surface TFR1 levels in CHO TRVb-1 cells and HepG2 cells were assessed. Data is presented as mean ± SEM (n=3). *p<0.01 compared to HepG2 cells (1-way ANOVA).

Fig.2 Basal levels of iron and hepcidin peptide secretion in CHO TRVb-1 cells 
Intracellular iron levels (a) and hepcidin secretion (b) in CHO TRVb-1 cells were measured by using the ferrozine assay and radioimmunoassay, respectively, under basal conditions. Data is presented as mean ± SEM (n=3). *p<0.05 and **p<0.01 compared to 30 min in CHO TRVb-1 cells; #p<0.04 and ##p<0.02 compared to HepG2 cells at 30 min and 24 h, respectively (2-way ANOVA). Analysis showed significant differences between cell-types (p=0.019) and for cell-type x time (p=0.039) (post-hoc analysis by Tukey’s method)

Fig. 3 Effect of iron supplementation on cell-surface expression of TFR1 in CHO TRVb-1 cells 
CHO TRVb-1 and HepG2 cells were treated with 5 g/L holo-Tf and cell-surface TFR1 was assessed by flow cytometry. Representative images of CHO TRVb-1 cells following treatment for 24 h and 48 h are depicted in ‘a’ and ‘b’, respectively. Data is presented as mean ± SEM (n=3). *p <0.01 compared to 24 hours in HepG2 cells (1-way ANOVA).

Fig.4 Effect of iron supplementation on intracellular iron levels and hepcidin secretion in CHO TRVb-1 cells
Intracellular iron levels (a & b) and hepcidin secretion (c & d) in CHO TRVb-1 cells were measured by using the ferrozine assay and radioimmunoassay, respectively. Data is presented as mean ± SEM (n=3). *p<0.01 compared to 30 min in CHO TRVb-1 cells; #p<0.02 compared to HepG2 cells at the corresponding time-point; ^p<0.05 compared to 4 h in CHO TRVb-1 cells (1-way ANOVA).

Fig.5 Gene expression studies in CHO TRVb-1 and HepG2 cells
mRNA expression levels of human TFRC and endogenous slc40a1 in CHO TRVb-1 cells upon holo-Tf deprivation (0 g/L) (a) and holo-Tf supplementation (b) are shown. Also, the effect of holo-Tf deprivation (c) and holo-Tf supplementation (d) in HepG2 cells has been shown. Data is presented as mean ± SEM (n=3). *p<0.05, **p<0.03 compared to 30 min; #p<0.01 compared to 4 h (1-way ANOVA). 

Fig.6 Effect of iron supplementation on mitochondrial activity in CHO TRVb-1 cells 
CHO TRVb-1 and HepG2 cells were treated with 0 g/L (a) and 5 g/L (b) holo-Tf and mitochondrial activity in the cells was determined by using the MTT assay. Data is presented as mean ± SEM (n=3).

Fig.7 Characterisation of CHO-endogenous slc40a1 
(a): Amplicons of slc40a1 in CHO TRVb-1 cells and rodents with primers (F1) and (R1) in the first round of sequencing have been shown. Here, lane 1= rat liver DNA (control), lane 2= mouse kidney cDNA (control), expected sizes of controls were 160 bp. Lane 3= CHO TRVb-1 DNA, Lane 4= negative control. Encircled product in lane 3 was purified and its sequence identity was confirmed as described in the methods section.
(b): The table shows percentage sequence similarities between the characterised CHO-slc40a1 sequences and slc40a1 sequences of related species. 
(c): The alignment underpins functional study of the characterised CHO- slc40a1 sequence. The characterised sequence was translated using the functional tool “TRANSLATE” available at web.expasy.org, and compared with ferroportin sequences of different species.
Key to alignment:
	Proposed transmembrane region 
	Proposed hepcidin binding domain 
	K253,Y302,Y303: amino acids affecting ferroportin degradation and internalisation 
	N144H, V162 ∆: Mutations that disruption ferroportin function
	* represents conserved amino acid between species
Fig.8 Conservation of hepcidin sequence amongst species
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Human      MTRAGDHNRQRGCCGSLADYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNSLLL 60
Mouse      ------------------------------------------------------------
Rat        MTKSRDQTHQEGCCGSLANYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNGLLL 60
Hamster    --------------------------------------------------------SLLL 4
                                                                                
Human      TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKHEL 120
Mouse      TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKNEL 60
Rat        TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKNEL 120
Hamster    TAVYGLVVAGSVLVA-----------------QTSLVVQNVSVILCGIILMMVFLHKNEL 47
           **************                  *************************:**

Human      LTMYHGWVLTSCYILIITIANIANLASTATAITIQRDWIVVVAGEDRSKLANMNATIRRI 180
Mouse      LTMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 120
Rat        LNMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 180
Hamster    LTMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 107
           *.******** **********************************:**:**:********
                                N144H             V162∆ 
         
Human      DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYVLLWKVYQKTPALAVKAGLK 240
Mouse      DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAALK 180
Rat        DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAALK 240
Hamster    DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAVLK 167
           ****************************************.**************** **


Human      EEETELKQLNLHKDTEPKPLEGTHLMGVKDSNIHELEHEQEPTCASQMAEPFRTFRDGWV 300
Mouse      VEESELKQLTSPKDTEPKPLEGTHLMGEKDSNIRELECEQEPTCASQMAEPFRTFRDGWV 240
Rat        VEESELKQLTSPKDTEPKPLEGTHLMGEKDSNIRELECEQEPTCASQIAEPFRTFRDGWV 300
Hamster    VEEAELKQLNLPKDTEPKSLEGTHLMGEKDSNIRELEHEQESTCASQIAEPFRTFRDGWV 227
           **:*****.  ******.******** *****:*** ***.*****:************
                      K253

Human      SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF 360
Mouse      SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF 300
Rat        SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSVLMGASAITGIMGTVAF 360
Hamster    SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLS---------------------- 265
           **************************************                      










Hamster Hepc-1 MAQSTKIQAACLLLLLIAPQLLRAATEGTRVRQPEALQPQHRTADQTDRTDRTLLIPKRT 
Hamster Hepc 2 MAQSTKIQAACLLLLLIASLA-SSTLLQQLVRQPEALQPQHRTKAQTDRTDRTLLIPKRT 
               ******************     ::     *************  ***************


Hamster Hepc-1 KRDSHFPICIFCCYCCGNFKCGVCCKT 87
Hamster Hepc-2 KRDSHFPICIFCCYCCGNFKCGVCCKT 86





Hamster Hepc-1 KRDSHFPICIFCCYCCGNFKCGVCCKT 
Hamster Hepc 2 KRDSHFPICIFCCYCCGNFKCGVCCKT 
Human Hepc     RRDTHFPICIFCCGCCHRSKCGMCCKT 
               :**:********* ** . ***:****


























Characterisation of hepcidin response to holotransferrin treatment in CHO TRVb-1 cells 




Transcriptomic similarities between chosen pre-characterised hamster mRNA sequences and corresponding transcripts in human, mouse and rat (supplementary Table 1) were ascertained via multiple sequence alignments using ClustalW2 (www.ebi.ac.uk (​http:​/​​/​www.ebi.ac.uk​)). Under the same principle, conserved nucleotides between human, mouse and rat slc40a1 mRNA sequences (accession numbers in supplementary Table 2) were identified and primers ATCGGATGTGGCACTTTGC (F1) and GCCACTTTAAGTCTNGCATTCT (R1) were designed and used to probe the CHO-genome. The obtained product was characterised by sequencing. Based on this characterised CHO-slc40a1 sequence and the conserved nucleotides between the mentioned three species, primers TAGCAGGCTCTGTTCTGG (F2) and CCATTATTCCAGTTATNGCTGATGC (R2) were designed. The resultant CHO-product was sequenced again. For gene expression analysis via real-time PCR, the characterised CHO-slc40a1 sequence was further used to design CHO-specific primers, namely, ATGGGTGCTCACTGTCTGCTA (CHO-FPN-F) and GCATTCATATCTGCTAATCTGCTTC (CHO-FPN-R). At every round of sequencing, each designed primer was checked for its gene specificity at the NCBI database with blastn and the characterised sequences of products were compared to corresponding pre-characterised sequences in the NCBI database to confirm their identity. 


Genes in Cricetulus griseus (hamster)	Human	Mouse	Rat
Transferrin receptor (L19142.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​304528?report=genbank&log$=nucltop&blast_rank=1&RID=M2KZDSA1016" \o "Show report for L19142.1​))	(NM_001128148.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​189458818?report=genbank&log$=nucltop&blast_rank=14&RID=M2KZDSA1016" \o "Show report for NM_001128148.1​))82%99%	(NM_011638.4 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​291045184?report=genbank&log$=nucltop&blast_rank=5&RID=M2KZDSA1016" \o "Show report for NM_011638.4​))87%100%	(NM_022712.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​281306745?report=genbank&log$=nucltop&blast_rank=4&RID=M2KZDSA1016" \o "Show report for NM_022712.1​))87%100%
Dihydrofolate reductase (M13477.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​191049?report=genbank&log$=nucltop&blast_rank=3&RID=WJP45HYX011" \o "Show report for M13477.1​))	(X00858.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​30780?report=genbank&log$=nucltop&blast_rank=8&RID=WJP45HYX011" \o "Show report for X00858.1​))83%65%	(J00386.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​193337?report=genbank&log$=nucltop&blast_rank=5&RID=WJP45HYX011" \o "Show report for J00386.1​))86%75%	(BC158583.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​165971602?report=genbank&log$=nucltop&blast_rank=15&RID=WJP45HYX011" \o "Show report for BC158583.1​))97%28%
Heat shock protein (M34561.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​191117?report=genbank&log$=nucltop&blast_rank=1&RID=M2SUD7P101N" \o "Show report for M34561.1​))	(NM_006597.3 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​24234684?report=genbank&log$=nucltop&blast_rank=1&RID=WJPR9M0201S" \o "Show report for NM_006597.3​))89%96%	(M19141.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​194034?report=genbank&log$=nucltop&blast_rank=11&RID=WJPHGJ3W016" \o "Show report for M19141.1​))93%90%	(NM_024351.2 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​81295400?report=genbank&log$=nucltop&blast_rank=6&RID=WJPHGJ3W016" \o "Show report for NM_024351.2​))93%90%
Ferritin (M99692.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​191071?report=genbank&log$=nucltop&blast_rank=1&RID=M2SYP1Z7011" \o "Show report for M99692.1​))	(NM_002032.2 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​56682958?report=genbank&log$=nucltop&blast_rank=1&RID=WJPT6CEU011" \o "Show report for NM_002032.2​))87%88%	(NM_010239.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​6753911?report=genbank&log$=nucltop&blast_rank=1&RID=WJPUY0MX016" \o "Show report for NM_010239.1​))91%99%	(BC097341.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​66911978?report=genbank&log$=nucltop&blast_rank=60&RID=WJPXCY21014" \o "Show report for BC097341.1​))90%99%
Alpha tubulin (M12252.1)	(NM_006009.2 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​17986282?report=genbank&log$=nucltop&blast_rank=2&RID=WJRJRYB401N" \o "Show report for NM_006009.2​))93%83%	(NM_011653.2 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​133892260?report=genbank&log$=nucltop&blast_rank=2&RID=WJRMTURU01S" \o "Show report for NM_011653.2​))95%83%	(NM_00104427)94%0.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​112984123?report=genbank&log$=nucltop&blast_rank=2&RID=WJRFYHPT01N" \o "Show report for NM_001044270.1​)99%

Table 1 Genomic similarities between hamster, human, mouse and rat. 






Species	mRNA/ protein sequence 	Accession number 	Source 
Human 	TFRC 	NM_001128148.1 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​nucleotide​/​189458818?report=genbank&log$=nucltop&blast_rank=14&RID=M2KZDSA1016" \o "Show report for NM_001128148.1​)	NCBI 








Chinese hamster 	Hepcidin	XP_003515358.1 and XP_007622562.1.	NCBI

Table 2 Accessions numbers of genes and proteins  































                                                                   5’ATCGGATGTG >>>
HumanSLC40A1_      ----------TTCCTTCTCTACCTTGGTCATTCTCTCTCTACTTGGGGAGATCGGATGTG 476
Mouseslc40a1_      ----------TTCCTCCTCTACCTTGGCCACTCTCTCTCCACTTGGGGGGATCGGATGTG 456
Ratslc40a1_        ----------TTCCTCCTCTACCTTGGCCACTCTCTCTCCACTTGGGGGGATCGGATGTG 416
                   ----------***** *********** ** ******** ******** ***********
                   GCACTTTGC >>> 3’ (F1) 
HumanSLC40A1_      GCACTTTGCGGTGTCTGTGTTTCTGGTAGAGCTCTATGGAAACAGCCTCCTTTTGACAGC 536
Mouseslc40a1_      GCACTTTGCAGTGTCTGTGTTTCTGGTGGAACTCTATGGAAACAGCCTTCTCTTGACAGC 516
Ratslc40a1_        GCACTTTGCAGTGTCTGTGTTTCTGGTGGAACTCTACGGAAACAGCCTCCTCTTGACAGC 476
                   ********* ***************** ** ***** *********** ** ********
                                                              AGCCTCCTCTTGACAGC
                                                     
                 
HumanSLC40A1_      AGTCTACGGGCTGGTGGTGGCAGGGTCTGTTCTGGTCCTGGGAGCCATCATCGGTGACTG 596
Mouseslc40a1_      TGTCTATGGACTGGTGGTGGCAGGCTCTGTTCTGGTCCTGGGAGCCATCATTGGTGACTG 576
Ratslc40a1_        TGTCTACGGGTTGGTGGTGGCAGGCTCTGTTCTGGTCCTGGGAGCCATCATTGGTGACTG 536
                    ***** **  ************* ************************** ********

                   TGTCTACGGGCTGGTGGTAGCAGGCTCTGTTCT 
                                 5' TAGCAGGCTCTGTTCTGG >>>3' (F2)

                     3’<<< TCTTACGNTCTGAATTTCACCG 5’ (R1) 
HumanSLC40A1_      GGTGGACAAGAATGCTAGACTTAAAGTGGCCCAGACCTCGCTGGTGGTACAGAATGTTTC 656
Mouseslc40a1_      GGTGGATAAGAATGCCAGACTTAAAGTGGCCCAGACGTCACTGGTGGTTCAGAATGTGTC 636
Ratslc40a1_        GGTGGATAAGAATGCCAGACTTAAAGTGGCCCAGACGTCCCTGGTGGTTCAGAATGTATC 596
                   ****** ******** ******************** ** ******** ******** **
                                           AGTGGCGCAGACTTCACTGGTGGTGCAGAACGTCTC
HumanSLC40A1_      AGTCATCCTGTGTGGAATCATCCTGATGATGGTTTTCTTACATAAACATGAGCTTCTGAC 716
Mouseslc40a1_      CGTCATCCTCTGCGGAATCATCCTGATGATGGTTTTCCTACACAAGAATGAGCTCCTGAC 696
Ratslc40a1_        AGTCATTCTCTGCGGGATCATCCTGATGATGGTTTTCTTACACAAGAATGAGCTTCTGAA 656
                    ***** ** ** ** ********************* **** **  ******* **** 
                   CGTCATTCTCTGCGGGATCATCCTGATGATGGTTTTCTTACACAAAAACGAGCTTCTGAC
HumanSLC40A1_      CATGTACCATGGATGGGTTCTCACTTCCTGCTATATCCTGATCATCACTATTGCAAATAT 776
Mouseslc40a1_      CATGTACCATGGATGGGTCCTTACTGTCTGCTACATCCTGATCATCACTATTGCAAACAT 756
Ratslc40a1_        CATGTATCATGGATGGGTCCTTACTGTCTGCTACATCCTGATCATCACCATTGCAAACAT 716
                   ****** *********** ** ***  ****** ************** ******** **
                   CATGTATCATGGATGGGTGCTCACTGTCTGCTACATCCTGATCATCACGATTGCAAACAT
                        5’ ATGGGTGCTCACTGTCTGCTA 3'>>> (CHO-FPN-F)

HumanSLC40A1_      TGCAAATTTGGCCAGTACTGCTACTGCAATCACAATCCAAAGGGATTGGATTGTTGTTGT 836
Mouseslc40a1_      TGCAAATTTGGCCAGTACTGCCACTGCGATCACAATCCAAAGGGACTGGATTGTTGTTGT 816
Ratslc40a1_        TGCGAATTTGGCCAGTACTGCCACTGCAATTACAATCCAAAGGGACTGGATTGTTGTCGT 776
                   *** ***************** ***** ** ************** *********** **
                   TGCAAATCTGGCCAGTACTGCTACTGCAATCACGATCCAAAGGGACTGGATTGTTGTTGT
HumanSLC40A1_      TGCAGGAGAAGACAGAAGCAAACTAGCAAATATGAATGCCACAATACGAAGGATTGACCA 896
Mouseslc40a1_      GGCAGGAGAAAACAGGAGCAGATTAGCAGACATGAATGCTACCATTAGAAGGATTGACCA 876
Ratslc40a1_        AGCAGGAGAAAACAGGAGCAGATTAGCAGACATGAATGCTACCATTAGAAGGATTGACCA 836
                    ********* **** **** * ***** * ******** ** **  *************
                   GGCGGGAGAGAACAGAAGCAGATTAGCAGATATGAATGCTACCATCAGAAGGATTGACCA
             (CHO-FPN-R) <<<  3’ CTTCGTCTAATCGTCTATACTTACG 5’
 
HumanSLC40A1_      GTTAACCAACATCTTAGCCCCCATGGCTGTTGGCCAGATTATGACATTTGGCTCCCCAGT 956
Mouseslc40a1_      GCTAACCAACATCCTGGCCCCCATGGCTGTCGGCCAGATTATGACATTTGGTTCTCCAGT 936
Ratslc40a1_        GCTAACCAACATCCTGGCCCCCATGGCTGTTGGCCAGATTATGACATTCGGTTCCCCAGT 896
                   * *********** * ************** ***************** ** ** *****
                   GCTAACCAACATCCTGGCCCCCATGGCTGTCGGCCAGATTATGACATTCGGTTCCCCAGT

HumanSLC40A1_      CATCGGCTGTGGCTTTATTTCGGGATGGAACTTGGTATCCATGTGCGTGGAGTACGTTCT 1016
Mouseslc40a1_      CATTGGCTGTGGTTTTATTTCCGGTTGGAATTTGGTGTCCATGTGTGTGGAGTACTTCTT 996
Ratslc40a1_        CATTGGCTGTGGTTTCATTTCTGGTTGGAATTTGGTGTCCATGTGTGTGGAGTACTTCTT 956
                   *** ******** ** ***** ** ***** ***** ******** ********* *  *
                   CATTGGCTGTGGTTTCATTTCGGGGTGGAATTTGGTGTCCATGTGTGTGGAGTACTTCTT

HumanSLC40A1_      GCTCTGGAAGGTTTACCAGAAAACCCCAGCTCTAGCTGTGAAAGCTGGTCTTAAAGAAGA 1076
Mouseslc40a1_      GCTCTGGAAGGTTTACCAGAAGACCCCTGCTCTGGCTGTAAAAGCTGCTCTCAAGGTAGA 1056
Ratslc40a1_        GCTCTGGAAGGTTTACCAGAAGACCCCTGCTCTGGCTGTAAAAGCTGCTCTCAAGGTAGA 1016
                   ********************* ***** ***** ***** ******* *** ** * ***
                   GCTCTGGAAGGTTTACCAGAAAACCCCTGCTCTGGCTGTGAAAGCTGTTCTCAAAGTAGA

HumanSLC40A1_      GGAAACTGAATTGAAACAGCTGAATTTACACAAAGATACTGAGCCAAAACCCCTGGAGGG 1136
Mouseslc40a1_      GGAGTCAGAACTGAAGCAGCTGACCTCACCTAAAGATACTGAGCCAAAACCTTTGGAGGG 1116
Ratslc40a1_        GGAGTCAGAACTGAAGCAGCTGACCTCACCTAAAGATACTGAGCCAAAACCTTTGGAGGG 1076
                   ***  * *** **** *******  * **  ********************  *******
                   GGAGGCAGAACTGAAGCAACTGAACTTACCTAAAGACACTGAGCCAAAATCTCTGGAGGG

HumanSLC40A1_      AACTCATCTAATGGGTGTGAAAGACTCTAACATCCATGAGCTTGAACATGAGCAAGAGCC 1196
Mouseslc40a1_      AACTCATCTAATGGGTGAGAAAGACTCCAACATCCGTGAACTTGAATGTGAACAAGAGCC 1176
Ratslc40a1_        AACTCACCTAATGGGTGAGAAAGACTCTAACATCCGTGAACTTGAATGTGAACAAGAACC 1136
                   ****** ********** ********* ******* *** ******  *** ***** **
                   AACTCATCTTATGGGTGAGAAAGACTCCAACATCCGTGAACTTGAACATGAGCAAGAGTC

HumanSLC40A1_      TACTTGTGCCTCCCAGATGGCTGAGCCCTTCCGTACCTTCCGAGATGGATGGGTCTCCTA 1256
Mouseslc40a1_      CACCTGTGCCTCCCAGATGGCAGAGCCCTTCCGCACTTTCCGAGATGGATGGGTCTCCTA 1236
Ratslc40a1_        CACCTGTGCCTCCCAGATCGCAGAACCCTTCCGCACTTTTCGAGATGGATGGGTCTCCTA 1196
                    ** ************** ** ** ******** ** ** ********************
                   TACGTGTGCCTCCCAGATCGCTGAGCCCTTCCGCACCTTTCGAGATGGGTGGGTCTCCTA

HumanSLC40A1_      CTACAACCAGCCTGTGTTTCTGGCTGGCATGGGTCTTGCTTTCCTTTATATGACTGTCCT 1316
Mouseslc40a1_      CTATAACCAGCCAGTGTTTCTGGCTGGCATGGGCCTGGCTTTCCTCTATATGACAGTCCT 1296
Ratslc40a1_        CTATAACCAGCCCGTATTTTTGGCTGGCATGGGCCTGGCTTTCCTCTATATGACAGTCCT 1256
                   *** ******** ** *** ************* ** ******** ******** *****
                   CTATAACCAGCCAGTGTTTCTGGCTGGCATGGGCCTGGCCTTCCTCTATATGACAGTCCT

HumanSLC40A1_      GGGCTTTGACTGCATCACCACAGGGTACGCCTACACTCAGGGACTGAGTGGTTCCATCCT 1376
Mouseslc40a1_      GGGCTTTGACTGTATCACTACAGGGTACGCCTACACTCAGGGGCTGAGTGGATCCATCCT 1356
Ratslc40a1_        GGGCTTCGACTGTATCACCACAGGATATGCTTACACTCAGGGACTGAGTGGTTCCATCCT 1316
                   ****** ***** ***** ***** ** ** *********** ******** ********
                   GGGCTTTGATTGCATCACCACAGGGTACGCCTACACTCAGGGACTAAGTGG

                          (R2)3’<<<CGTAGTCGNTATTGACCTTATTACC 5’
HumanSLC40A1_      CAGTATTTTGATGGGAGCATCAGCTATAACTGGAATAATGGGAACTGTAGCTTTTACTTG 1436
Mouseslc40a1_      TAGTATTTTGATGGGAGCATCAGCAATAACTGGAATAATGGGAACTGTGGCCTTCACCTG 1416
Ratslc40a1_        CAGTGTTTTGATGGGAGCATCAGCAATAACTGGAATAATGGGAACTGTGGCCTTCACTTG 1376
                    *** ******************* *********************** ** ** ** **

Fig.1 Characterisation of CHO-slc40a1 sequence
Partial alignment of slc40a1 mRNA sequences has been shown. Key to alignment:
	Sequence in CHO TRVb-1 cells characterised by primers (F1) and (R1) in first round of sequencing. 
	Sequence in CHO TRVb-1 cells characterised by primers (F2) and (R2) in second round of sequencing.
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Fig.2 Determination of iron in supplement
(a): Iron content in iron loaded transferrin was determined by 6 M urea PAGE. Lane 1: iron depleted transferrin; lane 2: iron loaded transferrin. The three species of iron-Tf, C-and N-monoferric and holo-Tf can be observed; with a major proportion of diferric-Tf. 



















 1      2    

























































Furin convertase cleavage site 
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